Technetium-99m-sestamibi scintigraphy compared with thallium-201 in evaluation of thyroid tumors.
Technetium-99m methoxyisobutylisonitrile (MIBI) is a myocardial perfusion imaging agent that has been reported to effectively localize in various tumors (e.g., lung and thyroid carcinomas and osteogenic sarcoma). To determine its usefulness in thyroid tumors, we compared 99mTc-MIBI with 201TI imaging. We evaluated 25 patients with thyroid tumors (papillary carcinoma in 11, follicular carcinoma in 2, follicular adenoma in 7, adenomatous goiter in 5). Fifteen metastatic lesions from differentiated thyroid carcinomas were also evaluated. Early (10 min after injection) and delayed images (120 min after injection) were obtained for both 99mTc-MIBI and 201TI scintigraphy. The early images showed very similar findings for both 99mTc-MIBI and 201TI. However, the delayed images showed that malignant tumors tended to retain more tracer agent than benign nodules. Marked retention was in 61.5% (8 of 13) of 201TI images and 53.8% (7 of 13) of 99mTc-MIBI images. For metastatic lesions from thyroid carcinomas, the findings for 99mTc-MIBI imaging were nearly identical to those for 201TI imaging. A slight difference in clarity was seen that may have been due to the effect of the 99mTc. Although 99mTc-MIBI scintigraphy does not have particularly good results in differentiating malignant from benign thyroid tumors, it may be useful in evaluating metastases or predicting recurrence because of its better imaging characteristics.